GALMED PHARMACEUTICALS LTD's ticker is GLMD and the CUSIP is M47238106. A total of 32 filers reported holding GALMED PHARMACEUTICALS LTD in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $696,000 | -54.1% | 145,694 | -29.3% | 0.64% | -48.6% |
| Q2 2019 | $1,515,000 | -10.0% | 206,099 | 0.0% | 1.24% | -3.1% |
| Q1 2019 | $1,684,000 | +17.4% | 206,099 | -1.9% | 1.28% | -21.5% |
| Q4 2018 | $1,434,000 | -50.2% | 210,000 | 0.0% | 1.63% | -33.0% |
| Q3 2018 | $2,881,000 | +15.3% | 210,000 | 0.0% | 2.44% | +14.6% |
| Q2 2018 | $2,499,000 | +1015.6% | 210,000 | +320.4% | 2.12% | +2809.6% |
| Q2 2016 | $224,000 | -30.0% | 49,947 | -23.2% | 0.07% | -43.8% |
| Q1 2016 | $320,000 | -35.4% | 65,000 | 0.0% | 0.13% | -29.3% |
| Q4 2015 | $495,000 | +2.5% | 65,000 | 0.0% | 0.18% | -10.2% |
| Q3 2015 | $483,000 | -26.1% | 65,000 | 0.0% | 0.20% | -2.8% |
| Q2 2015 | $654,000 | +6.9% | 65,000 | 0.0% | 0.21% | +18.5% |
| Q1 2015 | $612,000 | +62.3% | 65,000 | 0.0% | 0.18% | +20.3% |
| Q4 2014 | $377,000 | -32.6% | 65,000 | 0.0% | 0.15% | -31.8% |
| Q3 2014 | $559,000 | -11.7% | 65,000 | 0.0% | 0.22% | -23.0% |
| Q2 2014 | $633,000 | -15.1% | 65,000 | 0.0% | 0.28% | -26.9% |
| Q1 2014 | $746,000 | – | 65,000 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 1,799,694 | $1,224,000 | 0.06% |
| BRAVE ASSET MANAGEMENT INC | 11,470 | $8,000 | 0.00% |
| Western Wealth Management, LLC | 59,074 | $38,000 | 0.00% |
| PYA Waltman Capital, LLC | 1,000 | $1,000 | 0.00% |
| TSFG, LLC | 3,000 | $2,000 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 27,177 | $18,000 | 0.00% |
| Renaissance Technologies | 31,600 | $21,000 | 0.00% |
| MILLENNIUM MANAGEMENT LLC | 50,748 | $35,000 | 0.00% |
| CITIGROUP INC | 3,700 | $3,000 | 0.00% |
| UBS Group AG | 6,064 | $4,000 | 0.00% |